Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Regulatory
286 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Tagraxofusp | EU EMA | Blastic Plasmacytoid Dendritic Cell Neoplasm | Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). | approved | Jan 7, 2021 | ema |
| Tagraxofusp | US FDA | Blastic Plasmacytoid Dendritic Cell Neoplasm | ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 ) | approved | Dec 21, 2018 | openfda |
| Talquetamab | EU EMA | Multiple Myeloma | Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy.conditional | approved | Aug 21, 2023 | ema |
Data updated 17 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Dasatinib | 254 | 133 | 121 |
| Imatinib | 114 | 48 | 66 |
| Bosutinib | 89 | 30 | 59 |
| Imatinib Mesylate | 86 | 8 | 78 |
| Axitinib | 54 | 16 | 38 |
| Nilotinib | 50 | 17 | 33 |
| Sorafenib | 44 | 27 | 17 |
| Sunitinib | 39 | 36 | 3 |
| Venetoclax | 37 | 4 | 33 |
| Midostaurin | 33 | 28 | 4 |
| Ponatinib | 32 | 26 | 6 |
| Mercaptopurine | 31 | 2 | 28 |
| Doxorubicin |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| Talquetamab | US FDA | Multiple Myeloma | TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )accelerated | approved | Aug 9, 2023 | openfda |
| Tazemetostat | US FDA | Follicular Lymphoma | Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. | approved | Jan 23, 2020 | openfda |
| Tazemetostat | US FDA | Follicular Lymphoma | Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. | approved | Jan 23, 2020 | openfda |
| Teclistamab | EU EMA | Multiple Myeloma | Tecvayli is indicated in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. | approved | Aug 23, 2022 | ema |
| Teclistamab | US FDA | Multiple Myeloma | TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma: in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent ( 1 ). as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody ( 1 ). | approved | Oct 25, 2022 | openfda |
| Thalidomide | EU EMA | Multiple Myeloma | Thalidomide Lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ? 65 years or ineligible for high dose chemotherapy. Thalidomide Lipomed is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme (see section 4.4). | approved | Sep 19, 2022 | ema |
| Thalidomide | EU EMA | Multiple Myeloma | Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4). | approved | Apr 16, 2008 | ema |
| Thalidomide | US FDA | Multiple Myeloma | THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). | approved | Jul 16, 1998 | openfda |
| Trametinib | US FDA | Tumor-agnostic | the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.accelerated | approved | Mar 16, 2023 | openfda |
| Trametinib | US FDA | Tumor-agnostic | the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.accelerated | approved | May 29, 2013 | openfda |
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
| Treosulfan | US FDA | Myelodysplastic Syndrome | . Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS). | approved | Jan 21, 2025 | openfda |
| Treosulfan | US FDA | Acute Myeloid Leukemia | Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML). | approved | Jan 21, 2025 | openfda |
| Venetoclax | US FDA | Acute Myeloid Leukemia | In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. | approved | Apr 11, 2016 | openfda |
| Vinblastine | US FDA | Hodgkin Lymphoma | Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) | approved | Apr 29, 1987 | openfda |
| Vinblastine | US FDA | Mycosis Fungoides | Mycosis fungoides (advanced stages) | approved | Apr 29, 1987 | openfda |
| Vorasidenib | EU EMA | Grade 2 Follicular Lymphoma | Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section 5.1). | approved | Sep 17, 2025 | ema |
| Vorasidenib | US FDA | Grade 2 Follicular Lymphoma | VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ]. VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection. ( 1 ) | approved | Aug 6, 2024 | openfda |
| Vorinostat | US FDA | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 ) | approved | Oct 6, 2006 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Nov 14, 2019 | openfda |
| Ziftomenib | US FDA | Acute Myeloid Leukemia | KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 ) | approved | Nov 13, 2025 | openfda |
| 29 |
| 1 |
| 28 |
| Thioguanine | 29 | 0 | 28 |
| Melphalan | 24 | 0 | 24 |
| Quizartinib | 21 | 13 | 7 |
| Gilteritinib | 20 | 17 | 3 |
| Crizotinib | 17 | 12 | 5 |
| Cytarabine | 17 | 5 | 12 |
| Daunorubicin | 15 | 4 | 11 |
| Lestaurtinib | 14 | 13 | 1 |
| Vemurafenib | 14 | 13 | 1 |
| Tazemetostat | 13 | 13 | 0 |
| Tretinoin | 13 | 7 | 6 |
| Crenolanib | 12 | 11 | 1 |
| Ivosidenib | 12 | 12 | 0 |
| Prednisone | 11 | 11 | 0 |
| Revumenib | 11 | 4 | 7 |
| Chemotherapy | 10 | 8 | 2 |
| Ibrutinib | 10 | 4 | 6 |
| Methotrexate | 10 | 2 | 8 |
| Pexidartinib | 10 | 2 | 8 |
| Asparaginase | 9 | 0 | 9 |
| Larotrectinib | 8 | 8 | 0 |
| Ruxolitinib | 8 | 8 | 0 |
| Palbociclib | 7 | 7 | 0 |
| VTP-50469 | 7 | 0 | 7 |
| Azacitidine | 6 | 6 | 0 |
| Cobimetinib | 6 | 6 | 0 |
| Olaparib | 6 | 6 | 0 |
| Etoposide | 5 | 3 | 2 |
| Trametinib | 5 | 3 | 2 |
| Arabinosylguanine | 4 | 1 | 3 |
| Arsenic Trioxide | 4 | 1 | 3 |
| Asciminib | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Gemcitabine | 4 | 0 | 4 |
| Linifanib | 4 | 4 | 0 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| R3Mab | 4 | 4 | 0 |
| AG1295 | 3 | 3 | 0 |
| Bafetinib | 3 | 1 | 2 |
| Ceritinib | 3 | 1 | 2 |
| Dabrafenib/Trametinib Regimen | 3 | 3 | 0 |
| Entrectinib | 3 | 3 | 0 |
| Erlotinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| GSK126 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Pemigatinib | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Selumetinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| AGS324 | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| CTX-712 | 2 | 2 | 0 |
| Decitabine | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| Letetresgene Autoleucel | 2 | 2 | 0 |
| Lometrexol | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| NSC348884 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| RG7112 | 2 | 1 | 1 |
| Salinomycin | 2 | 2 | 0 |
| Sirolimus | 2 | 2 | 0 |
| Tandutinib | 2 | 1 | 1 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| Vincristine | 2 | 1 | 1 |
| Ziftomenib | 2 | 2 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| Adavosertib | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK Inhibitor TAE684 | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Atezolizumab | 1 | 1 | 0 |
| Avapritinib | 1 | 1 | 0 |
| AZ12908010 | 1 | 0 | 1 |
| Azathioprine | 1 | 0 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| BRAF Inhibitor | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Cetuximab | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cisplatin | 1 | 1 | 0 |
| Dabrafenib | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Dinaciclib | 1 | 0 | 1 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| Eprenetapopt | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| EPZ011989 | 1 | 1 | 0 |
| Erdafitinib | 1 | 1 | 0 |
| Fedratinib | 1 | 1 | 0 |
| Fexagratinib | 1 | 0 | 1 |
| Fludarabine | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Ipilimumab | 1 | 1 | 0 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Irinotecan | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| JQEZ5 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| Lenalidomide | 1 | 0 | 1 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MTOR Inhibitor | 1 | 1 | 0 |
| MVT Regimen | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Ningetinib | 1 | 1 | 0 |
| Nirogacestat | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Pacritinib | 1 | 1 | 0 |
| Panobinostat | 1 | 1 | 0 |
| PD173074 | 1 | 0 | 1 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Selinexor | 1 | 0 | 1 |
| Tamibarotene | 1 | 0 | 1 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tofacitinib | 1 | 1 | 0 |
| Tunlametinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Valproic Acid | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.